HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
Conditions
ADPKD
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cliniques Universitaires Saint-Luc, Brussels, Belgium
Contact: Study coordinator (Prof. Nathalie Demoulin)University Hospital Leuven, Leuven, Belgium
Contact: Study coordinator (Prof dr. B. Bammens)Hospital La Cavale Blanche, Brest, France
Contact: Study coordinator (Prof. dr. E. Cornec-Le Gall)Necker-Enfants Malades Hospital, Paris, France
Contact: Study coordinator (Prof dr. B. Knebelmann)Charité University Hospital, Berlin, Germany
Contact: Study coordinator (Prof J. Halbritter)University Hospital Cologne, Cologne, Germany
Contact: Study coordinator (Prof. dr. R.U. Müller)Med. Klinik und Poliklinik III, Universitätsklinikum Dresden., Dresden, Germany
Contact: Study coordinator (Alexander Paliege)Amsterdam University Medical Center, Amsterdam, Netherlands
Contact: Study coordinator (Prof dr. M. van Ittersum)University Medical Center Groningen, Groningen, Netherlands
Erasmus University Medical Center, Rotterdam, Netherlands
Contact: Study coordinator (dr. M. Salih)Fundación Puigvert, Barcelona, Spain
Contact: Study coordinator (Prof. dr. R. Torra)La Fundación Jiménez Díaz, Madrid, Spain
Contact: Study coordinator (María Vanessa Pérez Gómez)
Study leads
Prof. dr. R.T. Gansevoort
Principal Investigator
University Medical Center Groningen